Asian Spectator

Men's Weekly

.

BeauEver Secures NZ Prime Minister’s Support in Historic China Summit to Accelerate Global Skincare Expansion

SHANGHAI, CHINA - Media OutReach Newswire - 2 July 2025 - At the 2025 China–New Zealand Trade Innovation Summit, New Zealand Prime Minister, the Right Hon. Christopher Luxon, witnessed the offi...

JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS

TIANJIN, China, Aug. 17, 2022 /PRNewswire-AsiaNet/ -- - JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15...

New CTPAT security criteria highlight AIT Worldwide Logistics'...

ITASCA, Illinois, July 15, 2020 /PRNewswire-AsiaNet/ -- -- Security tech, leadership criteria for Customs Trade Partnership Against Terrorism renewal demonstrate logistics provider's commitm...

JCB appoints award winning B2B agency, Transmission, to lead JCB's brand evolution in Europe

LONDON, Oct 12, 2021 - (JCN Newswire) - Highlights: - JCB, the major global payment brand and credit card issuer in Japan with 140 million global cardmembers, has appointed global B2B mark...

Differently Abled Musician Emmanuel Kelly Launches Outlyer Ent...

LONDON, May 9, 2022 /PRNewswire-AsiaNet/ -- Emmanuel Kelly, differently-abled singer, actor, speaker and entrepreneur, announces the launch of his new business, Outlyer Entertainment with ad...

Cyborg Systems Develops COVID-19 Tracking Software

DUBAI, UAE, March 31, 2019, /PRNewswire-AsiaNet/-- On 16th March, 2020, in his opening remarks, WHO Director-General stated unequivocally that urgent escalation in testing, isolation and con...

RICOH establishes strategic partnership with Macroview Telecom, a HGC Group Company and Check Point

Launches Ricoh Cyber Security Management Service – the New Security Operations Center and Cyber Security Solutions Dismantling the Fallacy of Digital Business, Blocking the Network Vul...

Ethernity CLOUD Announces Results of Recent Token Pre-Sale

MUNICH, GERMANY / ACCESSWIRE, Aug 23, 2021 - (ACN Newswire) - Ethernity CLOUD is pleased to announce the successful completion of their token presale round. They have sold 90% of the availa...

Chiba Prefectural Government Sending Out Information through "...

CHIBA, Japan, Mar. 25, 2019 /Kyodo JBN - AsiaNet/ -- Chiba Prefecture, home to Narita International Airport, is transmitting information through the "Chiba-no Miryoku Hasshintai" ("team to p...

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20

TOKYO, Mar 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ.The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research work that has contributed to medicine through the innovative development of a pharmaceutical drug or applicable technology related to the pharmaceutical sciences. Award recipients are evaluated by the PSJ based on the ingenuity of the research itself as well as the effectiveness and safety of the related pharmaceutical product(s) or the innovativeness of the related medical treatment or treatment technology. The PSJ Award for Drug Research and Development was introduced by the PSJ in 1988, with Eisai previously receiving the award for drug discovery research in 1998 on donepezil hydrochloride, an Alzheimer's disease treatment, and in 2013 on eribulin mesylate, an anti-cancer agent.The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows. First, Eisai researchers created lenvatinib as a new type of kinase inhibitor with type V binding mode through a creation of the original screening models reflecting human disease and refined optimization of leading compounds. Furthermore, lenvatinib mesylate demonstrated antitumor activity against various types of cancer in clinical trials, which was accomplished with strategic application of drug properties to selectively inhibit kinases associated with tumor growth and pathogenic angiogenesis. At the time of application for the award, lenvatinib mesylate received approval as a treatment for refractory thyroid cancer, unresectable hepatocellular carcinoma, and advanced renal cell carcinoma. Finally, lenvatinib discovery research realized an innovative drug that received the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and holds high potential to contribute to anticancer therapy worldwide.Currently, lenvatinib has been approved as a treatment for refractory thyroid cancer in more than 60 countries including Japan, the United States, and in Europe; as a treatment for unresectable hepatocellular carcinoma in more than 55 countries including Japan, the United States, in Europe, China and in Asia; as well as in combination with everolimus as a treatment for advanced renal cell carcinoma (second-line) in more than 50 countries including the United States, in Europe and in Asia. Additionally, it is also approved in the combination treatment of lenvatinib plus KEYTRUDA (pembrolizumab) for advanced endometrial carcinoma in the United States, Australia, and Canada.Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to exploring the potential clinical benefits of lenvatinib and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Kamu nyaman curhat dengan AI? Hati-hati kena gangguan mental

Seorang perempuan sedang duduk sambil curhat dengan robot humanoid AI di sebuah ruang tamu.VesnaArt/Shutterstock● Kaum muda kini sering menjadikan ‘chatbot’ AI sebagai teman curhat.&...

Cemas saat berulang tahun? Simak tip psikolog untuk hadapi ‘birthday blues’

DavideAngelini/ShutterstockUlang tahun biasanya jadi momen membahagiakan penuh dengan tawa, perayaan, dan hadiah. Namun, tak jarang menjelang ulang tahun, kita justru merasa sedih.Ulang tahun dapat me...

Kenapa calon pengantin perlu cek kesehatan sebelum menikah?

● Cek kesehatan pranikah merupakan pemeriksaan kesehatan bagi calon pengantin.● Prosedur ini bisa cegah penularan infeksi seksual hingga penyakit keturunan.● Sejumlah daerah menjadik...